Physician profile
Robert E Cone
NPI 1467178418
$2,163.08
in general payments reported to CMS, 2019-2025
16 companies · $1,204 in 2025
The $1,204 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $127 · 2024: $832 · 2025: $1,204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,163.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $988.92 | 2024-2025 | Inceptiv, Intellis Adaptivestim |
| Boston Scientific Corporation | $398.84 | 2024-2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Collegium Pharmaceutical, INC. | $299.42 | 2024-2025 | Belbuca |
| Si-Bone, INC. | $96.05 | 2025 | |
| Pfizer INC. | $80.00 | 2023-2024 | |
| Amgen INC. | $60.24 | 2024-2025 | Evenity, Prolia, Prolia |
| Novartis Pharmaceuticals Corporation | $54.92 | 2023-2024 | |
| Abbvie INC. | $49.61 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $21.33 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.10 | 2023 | Xifaxan |
| Axsome Therapeutics, INC. | $20.54 | 2025 | Symbravo |
| Scpharmaceuticals INC. | $17.97 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.51 | 2023 | Stiolto Respimat |
| Merck Sharp & Dohme LLC | $14.50 | 2024 | Recarbrio, Zerbaxa |
| Janssen Pharmaceuticals, INC | $13.56 | 2024 | Xarelto |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $11.57 | 2023 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Cone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.